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Abstract 
BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) is a pyrimidine catabolic 
enzyme involved in the initial and rate-limiting step of the catabolic pathway of toxic 
metabolites of 5-fluorouracil (5-FU). Several studies have reported that deficiency of DPD 
and polymorphisms of its gene are related to 5-FU toxicities and death. Association between 
serum concentration of 5-FU and its related toxicity has also been previously demonstrated. 
Hence, this study aims to understand the role of DPYD variants in serum level of 5-FU and 
the risk of developing toxicity to prevent adverse reactions and maximize therapy outcome 
for personalized medicine. METHODS: A total of 26 patients comprising 3 different ethnic 
groups (Malay, Chinese, and Indian) diagnosed with colorectal cancer and treated with 5-FU 
chemotherapy regimen from local hospital were recruited. Polymerase chain reaction and 
denaturing high-performance liquid chromatography methods were developed to screen 
polymorphisms of DPYD gene. High-performance liquid chromatography-based 
quantification assay was developed to measure the serum concentration of 5-FU among these 
patients. RESULTS: Patients with DPYD genotypes of deficient enzyme activity had higher 
median serum levels of 5-FU compared with normal DPD group (median, 11.51 mcg/mL; 
95% confidence interval, 10.18-16.11 versus median, 0.83 mcg/mL; 95% confidence interval, 
0.55-5.90, Mann-Whitney U test; P = 0.010). Patients with neutropenia (n = 11) had 
significantly higher serum concentrations of 5-FU as compared with those with normal white 
blood cell count (n = 15) (Mann-Whitney U test, P = 0.031). Combined regression analysis 
showed that the predictive power of DPYD*5 (rs1801159) and 1896 T>C (rs17376848) for 
serum concentrations of 5-FU in the studied group was 36.6% (P = 0.04). Similarly, DPYD*5 
and 1896 T>C accounted for 29.9% of the occurrences of neutropenia (analysis of variance, P 
= 0.017). CONCLUSIONS: This study revealed that DPYD*5 (rs1801159) and 1896 T>C 
(rs17376848) are potentially useful predictive markers of patients' responses to 5-FU 
chemotherapy. Pharmacogenotyping is therefore recommended to guide dosing of 5-FU and 
prevent neutropenia. 
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